In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ACVC Biomarker Talks

A project from the ACVC Biomarkers Study Group

Association for Acute CardioVascular Care
Acute Cardiac Care

A series of concise and interactive online events covering the full spectrum of biomarkers.

Each talk is followed by an editorial article published in the European Heart Journal - Acute CardioVascular Care.



What are the ACVC Biomarker Talks?

Smart student learning using internet and headphonesThis series was designed by course directors Christian Müller and Nicholas Mills, chair and co-chair of the ACVC Study Group on Biomarkers.

 

The talks, in a nutshell:

  • Live and interactive online events covering each topic in the biomarker field;
  • Each talk will be moderated by Christian Mueller and Nicholas Mills, and presented by one expert;
  • Each talk will last for 30 minutes and include a 15-20 minute state-of-the-art presentation and 10-15 minute discussion with the audience;
  • The on-demand video will be available 24 hours after the live event.

Season 2 (2023)

Find out about and register for these upcoming talks.

26 April 2023 - High sensitivity cardiac troponin in stable ASCVD 

Learning objectives:

  • appreciate the use of high-sensitivity concentrations of cardiac troponin T or cardiac troponin I as a quantitative marker of chronic cardiomyocyte injury in stable ASCVD;
  • gain insights into how management of patients with stable ASCVD could be facilitated by using high sensitivity cardiac troponin T or cardiac troponin I; 
  • understand the need for additional investigation to identify the predominate cardiac pathology underlying increased high sensitivity cardiac troponin T or cardiac troponin I concentration in stable ASCVD; and
  • appreciate finding answers to the remaining questions regarding the possible use of high sensitivity cardiac troponin T or cardiac troponin I for stable ASCVD.  

 

31 May 2023 - How to use cardiac troponin T or cardiac troponin I in noncardiac surgery

Learning objectives:

  • understand the incremental value of using cardiac troponin T or cardiac troponin I concentrations for the preoperative risk assessment of complications and perioperative mortality in high-risk patients;
  • appreciate the problem of unacceptably high perioperative mortality;
  • understand how early detection and early therapy of cardiac complications – including perioperative myocardial injury (PMI) – can reduce unacceptably high perioperative mortality; and
  • learn the workup procedure for patients who develop PMI after noncardiac surgery.
June 2023 -Troponin back to basics  

Learning objectives:

  • To understand the biology of cardiac troponin T and I in healthy individuals
  • To get insights into current concepts of the pathophysiology underlying the release of cardiac troponin T and I into the systemic circulation in acute myocardial infarction
  • To get insights into current concepts of the pathophysiology underlying the release of cardiac troponin T and I into the systemic circulation in other acute cardiac disorders, such as takotsubo syndrome
  • To get insights into current concepts of the pathophysiology underlying the release of cardiac troponin T and I into the systemic circulation during aging and in chronic cardiac disorders

 

 Watch season 1 (2022)

 14 episodes available

About the ACVC Study Group on Biomarkers

Background

The ACVC Study Group on Biomarkers was established by Kristian Thygesen (DK) in 2005 with the intention of creating a support group for the Global Task Force for the Definition of Myocardial Infarction (later called Universal Definition of Myocardial Infarction - UDMI).

In addition to supporting the UDMI, this group became successful and independent and now focuses on the proper clinical application of cardiac biomarkers including troponins, natriuretic peptides, and inflammatory and thrombotic markers in acute cardiac care.

Objectives

  • disseminating  knowledge about the proper clinical application of cardiac biomarkers in acute cardiovascular care; 
  • advising on the appropriate application of biomarkers in cardiovascular research;
  • creating recommendations/guidelines for implementation of cardiac biomarkers in acute cardiac care; and
  • being a counselling source for authorities regarding the appropriate clinical use of cardiac biomarkers.